Table 1.
Sepsis therapy, a catalog of failures.
| Target | Strategy | References |
|---|---|---|
| Lps/Endotoxin | HA-1A | Ziegler et al., 1991 |
| E5531 | Bunnell et al., 2000 | |
| Anti-CD14 | Reinhart et al., 2004 | |
| Eritoran | Opal et al., 2013 | |
| Polymyxin B | Payen et al., 2015 | |
| conjugate | ||
| Endocrinopathy | Methylprednisolone | Bone et al., 1989 |
| Vasopressin | Ohsugi et al., 2016 | |
| Hypercoagulability /Disseminated Intravascular Coagulation (DIC) | Activated Protein C | Bernard et al., 2001 |
| Anti-thrombin | Warren et al., 2001 | |
| Heparin | Zhang and Ma, 2006 | |
| Thrombomodulin | Hagiwara et al., 2016 | |
| Cytokines | Anti-TNF-α | Tracey et al., 1987 |
| IL-1 receptor | Fisher et al., 1994 | |
| Antagonists | ||
| Soluble TNF-α receptor | Borrelli et al., 1996 | |
| Diacerhein | Calisto et al., 2012 | |
| Eicosanoids | Ibuprofen | Bernard et al., 1997 |
| Nitric Oxide | L-NMMA | Petros et al., 1994 |
| Oxidat1ve Stress | Statins | Patel et al., 2012 |
| Selenium | Sakr et al., 2014 | |
| Nf-Kb Transcription | Curcumin | Zhong et al., 2016 |
| Apoptosis | Caspase inhibitors | Weber et al., 2009 |
Most, if not all, were targeting inflammation including caspase inhibitors. Caspases do have a central role in inflammation (Mandal et al., 2018).